Vaxdyn
Vaxdyn is dedicated to preventing and alleviating the global health crisis caused by antibiotic-resistant bacteria through the development of safe and effective vaccines. The company collaborates internationally to develop multi-valent vaccines targeting bacterial pathogens, with a focus on high-risk populations and global health impact.
Industries
Nr. of Employees
small (1-50)
Products
AcinetoVax (VXD001)
An inactivated, LPS‑null (endotoxin‑free) whole‑cell vaccine candidate developed to prevent infections caused by Acinetobacter baumannii.
KapaVax (VXD005)
An inactivated, LPS‑null whole‑cell vaccine candidate based on A. baumannii cells engineered to display conserved antigens from Pseudomonas aeruginosa and Klebsiella pneumoniae on the cell surface.
AcinetoVax (VXD001)
An inactivated, LPS‑null (endotoxin‑free) whole‑cell vaccine candidate developed to prevent infections caused by Acinetobacter baumannii.
KapaVax (VXD005)
An inactivated, LPS‑null whole‑cell vaccine candidate based on A. baumannii cells engineered to display conserved antigens from Pseudomonas aeruginosa and Klebsiella pneumoniae on the cell surface.
Services
Collaborative vaccine research and development
Partnerships with academic and industry groups to co‑develop vaccine candidates and progress programs toward clinical or field trial milestones.
Grant‑driven program management
Management of grant awards and milestone‑based programs funded by public and philanthropic agencies to advance vaccine candidates.
Collaborative vaccine research and development
Partnerships with academic and industry groups to co‑develop vaccine candidates and progress programs toward clinical or field trial milestones.
Grant‑driven program management
Management of grant awards and milestone‑based programs funded by public and philanthropic agencies to advance vaccine candidates.
Expertise Areas
- Vaccine development for antibiotic‑resistant bacteria
- Multivalent / multi‑antigen vaccine platforms
- Preclinical development and Phase 1 preparedness
- One‑Health vaccine strategies (human and veterinary)
Key Technologies
- Inactivated whole‑cell vaccines (LPS‑null, endotoxin‑reduced)
- Cell‑surface antigen display
- Multi‑antigen vaccine platform
- Preclinical animal models and field trial readiness